PDCD1 and neoplasm: Pursuant to this, we reasoned that CM-272-induced sustained IFN-I/II signaling and/or factors like IL-10 and TGF-β could indeed hinder tumor antigen presentation by tumor-resident DCs, thereby restraining successful combination therapy of CM-272 and PD-1 inhibition (60, 74–81).